EGFR 21L858R mutation positive for advanced NSCLC
Conditions
Interventions
experimental group:Gefitinib combined with bevacizumab
control group:Gefitinib monotherapy
Sponsors
Ya'an People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed non-squamous non-small cell lung cancer, and the use of NGS detection suggested an exon mutation in EGFR 21L858R. 2. There were measurable lesions according to RECIST 1.1. 3. The investigators determined that stage IIIB (intolerance to radiotherapy) and stage IV (including asymptomatic brain metastases) required targeted therapy, including patients with recurrence or progression after initial treatment or chemotherapy. 4. Aged >= 18 years, male or female. 5. ECOG physical state score is 0 ~ 2. 6. Serum hemoglobin >= 100g/L, platelet >= 10 x 10^9/L, neutrophil absolute count >= 1.5 x 10^9/L. 7. Serum creatinine = 60 mL/ min. 8. Serum bilirubin <= 1.5 times UNL, AST (SGOT) and ALT (SGPT) <= 2.5 times UNL, alkaline phosphatase <= 5 times UNL. 9. Normal coagulation function (PT extension no more than 3s, APTT extension no more than 10s) 10. The patients signed a formal informed consent to demonstrate their understanding that the study was consistent with the hospital's policy and ethical requirements.
Exclusion criteria
Exclusion criteria: 1. Squamous cell or carcinoid carcinoma of the lung. 2. NGS detection suggested simultaneous combination of EGFR 19del deletion, EGFR18, and 20 exon mutations. 3. Have received other targeted drugs or immunotherapy. 4. Pregnant or lactating women. 5. Patients with mental disorders or unable to obtain valid data through regular follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective remission rate;The quality of life; | — |
Countries
China
Contacts
Public ContactTao Liu
Ya'an People's Hospital
Outcome results
None listed